-
Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China
•
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of its non-nucleoside cytomegalovirus (CMV) inhibitor Prevymis (letermovir) in China. The drug received market approval in December 2021 for the prevention of CMV infection and CMV disease in adult recipients with CMV seropositive [R+] undergoing allogeneic…
-
BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording USD304.5 million in product revenues, a 120% increase compared to USD138.6 million from the same period last year. The growth was primarily driven by strong sales of its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib)…
-
Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
•
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have announced a license and collaboration agreement. Under the deal, Sanofi will license two of its drugs to Innovent for development in China, alongside Innovent’s PD-1 inhibitor Tyvyt (sintilimab). Sanofi will also invest EUR300 million (USD306…
-
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
•
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a first quarterly dip in global revenues in two years. Global sales revenues were down 1% year-on-year (YOY) in constant currency terms to USD6.488 billion. This decline was primarily due to the full impact of generic…
-
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
•
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year (YOY) increase in global sales to DKK83.3 billion (USD11.42 billion) in constant exchange rate terms. The company saw strong sales growth in International Operations, up 10% YOY, and in North America, up 24% YOY. Diabetes…
-
Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a memorandum of understanding to collaborate with Hong Kong Science & Technology Park (HKSTP) and Shanghai Biomedicine Fund, a RMB 50 billion (USD 11.44 billion) municipal industry fund approved by the Shanghai government and initiated by…
-
Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and clinical observation for the Phase I clinical study of RAY1216, an innovative oral therapy for the novel coronavirus developed by its subsidiary Guangdong Raynovent Biotech Co., Ltd. The study results demonstrated good safety and pharmacokinetic…
-
CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA) in acute ischemic stroke has reached the pre-set primary endpoint. Study DetailsThe multi-center, prospective, randomized, open, blinded, non-inferiority Phase III clinical study was designed to…
